Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (RECEF) Company Profile & Overview
Explore Recce Pharmaceuticals Ltd’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Recce Pharmaceuticals Ltd (RECEF) Company Profile & Overview
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.